GlassScriptPhysician profile
Kristi Hare
NPI 1679871172
$2,688.08
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $916 · 2023: $740 · 2024: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $907.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.58 | 2021-2023 | |
| Amgen INC. | $302.40 | 2021-2024 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $224.12 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Janssen Pharmaceuticals, INC | $216.82 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $192.53 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.51 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $138.26 | 2021-2022 | |
| Novo Nordisk INC | $124.66 | 2021-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $105.18 | 2021-2023 | Shingrix |
| Abiomed | $79.30 | 2023-2024 | Impella |
| Abbott Laboratories | $68.70 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.70 | 2022-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $60.55 | 2021 | |
| Esperion Therapeutics, INC. | $51.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $51.40 | 2021-2024 | Farxiga |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.09 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $39.36 | 2022 | |
| Sumitomo Pharma America, INC. | $39.26 | 2023 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $39.22 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $38.52 | 2021-2023 | Steglatro, Belsomra |
| Edwards Lifesciences Corporation | $34.18 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Mayne Pharma Commercial LLC | $33.07 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $24.57 | 2023 | Rexulti |
| Sun Pharmaceutical Industries INC. | $23.53 | 2021 | |
| Exact Sciences Corporation | $21.73 | 2023 | Cologuard Collection Kit |
| Radius Health, INC. | $21.07 | 2021 | |
| Biogen, INC. | $19.68 | 2021 | |
| Astellas Pharma US INC | $16.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.92 | 2022 | |
| Boston Scientific Corporation | $14.21 | 2022 | |
| Eisai INC. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristi Hare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.